Back to All News & Events

TPP Alberta Steering Committee approves two drug list changes

Back to Messenger
March Messenger 2021, TPP Alberta | Posted March 11, 2021

At their most recent meeting, the TPP Alberta Steering Committee approved the move of two buprenorphine products from Type 1 to Type 2 drugs and the addition of Antibiotics to the Type 2 drug list.

Sublocade (injectable) and Probuphine (implant) are long-acting formulations of buprenorphine, typically used as Opioid Agonist Treatment for Opioid Use Disorders. These products are administered directly by a healthcare provider within specialized settings and the risk for diversion or misuse with these products is considered low. Both the products continue to be monitored through Netcare’s Pharmaceutical Information Network (PIN). With this change, TPP Alberta registration and the use of a TPP form will not be required to prescribe these products.

In addition, TPP Alberta recognizes antimicrobial resistance as an important issue of public health concern. To do its part to support optimized use, TPP Alberta has added antibiotics to its Type 2 drug list. These medications will be monitored through Netcare’s PIN. Use of a TPP form or registration with TPP Alberta will not be required for prescribing antibiotics.

Questions? Please email TPP Alberta.

Comments for this post are now closed. If you would like to share your feedback on this topic, please email